NCT05997238View on ClinicalTrials.gov

Evaluation of the Effect of Triamcinolone at Different Doses on LIA During TKA

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

February 12, 2024

Study Completion Date

May 1, 2024

Conditions
Osteoarthritis, Knee
Interventions
DRUG

without triamcinolone

The preparation contains only the basic formula. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.

DRUG

20mg triamcinolone

20mg triamcinolone was added to the preparation. Mix 20mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.

DRUG

40mg triamcinolone

40mg triamcinolone was added to the preparation. Mix 40mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.

DRUG

80mg triamcinolone

80mg triamcinolone was added to the preparation. Mix 80mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.

Trial Locations (1)

100181

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Peking University Third Hospital

OTHER